


Research Article

Pediatric Febrile Urinary Tract Infection Caused by ESBL Producing *Enterobacteriaceae* Species

Asnakech Agegnehu,¹ Mesfin Worku,² Demiss Nigussie,³ Birhanu Lulu,¹ and Birkneh Tilahun Tadesse ⁴

¹Microbiology Laboratory, Hawassa University Comprehensive Specialized Hospital, Ethiopia

²School of Medical Laboratory Science, College of Medicine and Health Sciences, Hawassa University, Ethiopia

³Department of Medical Laboratory Science, College of Medicine, Medicine and Health Sciences institute, Debrebirhan University, Ethiopia

⁴Department of Pediatrics, School of Medicine, College of Medicine and Health Sciences, Hawassa University, Ethiopia

Correspondence should be addressed to Birkneh Tilahun Tadesse; birknehtilahun@gmail.com

Received 8 October 2020; Revised 19 November 2020; Accepted 25 November 2020; Published 2 December 2020

Academic Editor: Cem Karadeniz

Copyright © 2020 Asnakech Agegnehu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Over the past decade, drug resistance pattern has worsened for many of the uropathogens due to overuse of antibiotics for empiric treatment. The burden of extended spectrum beta-lactamase (ESBL) producing *Enterobacteriaceae* associated urinary tract infections (UTI) has become increasingly more common, limiting treatment options among children presenting with febrile UTI. We investigated the burden and correlates of ESBL producing *Enterobacteriaceae* associated UTI among children and antibacterial resistance pattern. **Methods.** 284 midstream urine specimens were collected using standard aseptic techniques from 284 children who were diagnosed with suspected UTI. Urine culture and bacteria isolation were performed following standard bacteriological techniques. The Kirby-Bauer disk diffusion technique and the double-disc synergy test were used to investigate antibiotic susceptibility and presence of ESBL production. **Results.** UTI was confirmed using a positive urine culture for a relevant pathogen in 96/284 (33.8%) of the cases. *Enterobacteriaceae* accounted for 75% (72/96) of etiologies of UTI in children. The most frequent *Enterobacteriaceae* spp. were *E. coli*, 44.4% (32/72) and *K. pneumonia*, 27.8% (20/72). The overall multidrug resistance rate was 86.1% (62/72). ESBL-producers accounted for 41.7% (30/72) of the isolated *Enterobacteriaceae*. ESBL producing *K. pneumonia* and *E. coli* isolates accounted for 70% (14/20) and 37.5% (12/32), respectively. History of UTI in the past 1 year (adjusted odds ratio (AoR) = 0.08, 95%CI (0.01 – 0.57)) and medium family wealth index (AoR = 0.03, 95%CI (0.00 – 0.27)) protected from infection with ESBL-producing *Enterobacteriaceae*. **Conclusion.** ESBL production was more common in *K. pneumonia* and appeared to be a major factor contributing drug resistance UTI in children. The findings call for the need to incorporate ESBL testing in the routine clinical practice. The resistance level to commonly prescribed first-line antibiotics observed within *Enterobacteriaceae* was alarming calling for strengthened antimicrobial stewardship.

1. Introduction

Urinary tract infection (UTI), which is commonly caused by *Enterobacteriaceae* like *Escherichia coli* (*E. coli*) and *Klebsiella species* and other Gram-negative bacteria, is one of the commonest causes of febrile illnesses in children [1, 2]. Extended spectrum β -lactamase (ESBL) producing *Enterobacteriaceae* causing UTI have been associated with prescription of

broad-spectrum antibiotics, which further exacerbate the challenge of antimicrobial resistance (AMR) [3].

In several settings, the occurrence of ESBL-producing bacterial infections like *E. coli* and *Klebsiella species* were described as a pandemic [1, 4, 5]. ESBLs are plasmid-mediated enzymes, which confer resistance to Gram-negative bacteria [6], through three mechanisms—first, β -lactam cannot reach penicillin-binding proteins (PBP); second, decreased affinity to PBPs;

and third, β -lactamases destroy the drug [7]. β -lactamase enzymes destroy inactivate β -lactam containing antibiotics, and ESBLs contain serine. These enzymes can hydrolyze penicillin, cephalosporin, aztreonam, and monobactam antibiotics making them ineffective. Cephamycin groups including cefoxitin and cefotetan and carbapenems including imipenem, meropenem, and ertapenem are not hydrolyzed by ESBLs and are hence considered as the drugs of choice for treating ESBL-producing *Enterobacteriaceae* [8]. However, these drugs are not readily available; and, in settings where diagnostics for ESBL producing *Enterobacteriaceae* are limited, targeting treatment becomes a challenge.

Circulation of ESBL-producing *Enterobacteriaceae* in the community and healthcare settings is a significant global challenge as this could be associated with increasing trends of AMR, which is even more significant in the sub-Saharan African region [9]. Furthermore, high levels of AMR related to ESBL-producing *Enterobacteriaceae* complicate individual patient care increasing the mortality and morbidity associated with common infectious diseases in children like UTI [10]. Of note, the alarming AMR trend is partly due to the irrational use of antibiotics in resource-limited settings which further leads to more selective pressure drug resistance [7, 11].

There is limited data on the extent of infections among children caused by ESBL-producing *Enterobacteriaceae*. We investigated the prevalence and correlates of pediatric UTI caused by ESBL-producing *Enterobacteriaceae* at a tertiary hospital. The findings will have a critical importance to guide empiric use of antibiotics in the pediatric population in the setting. It will also shed light on the importance of routine testing for ESBL-production in pediatric urine samples.

2. Methods and Materials

2.1. Study Setting and Participants. A cross-sectional study was conducted from February 1, 2018, to July 30, 2018, among children presenting to the outpatient department of Hawassa Comprehensive Specialized Hospital, which is a tertiary referral facility in southern Ethiopia.

Included were children below the age of 15 years with clinically suspected UTI defined as those with at least one of the signs and symptoms of urinary tract infection including frequency, urgency, dysuria, abdominal pain, back pain, and fever ($>38.0^{\circ}\text{C}$). Participants who received antibiotics within two weeks before presentation to the hospital were excluded.

2.2. Sample Size. Sample size was calculated using single-population proportion formulae considering the prevalence of extended spectrum β -lactamase (ESBL) producing *Enterobacteriaceae* of 78.6% [12]. Using survey methods, 10% non-response rate and 95% confidence interval, a final sample size of 284 subjects with suspected UTI was estimated.

2.3. Data Collection

2.3.1. Sociodemographic and Clinical Data. Sociodemographics including age (years), sex, residence, parental education and occupation, living standard, and clinical history of participants such as hospital admission and history of UTI within the past 12 months were recorded.

2.3.2. Laboratory Data Collection. A total of 284 early morning midstream (MSU) and catheterized urine samples were collected using properly labelled sterile, clean, transparent, screw-capped, wide-mouth plastic cups. Samples were transported to the microbiology laboratory within two hours of collection. Standard wire loop of 1 μl diameter was used to inoculate approximately 0.001 mL urine on 5% sheep Blood agar (OXOID Ltd, England) and MacConkey agar (OXOID Ltd., Basingstoke, United Kingdom) plate which were incubated aerobically at 37°C for 24 hrs.

Significant bacterial growth was determined on Blood agar plate when a single midstream or catheterized urine culture yields $>10^5$ CFU/mL [13]. Macroscopic examination for hemolysis, changes in physical appearance on differential media, and colony characteristics were recorded to help in identification. Furthermore, Gram reaction, morphology, and colony arrangement were recorded. Biochemical tests including Indole production, sugar fermentation, H_2S and gas production, citrate utilization, motility test, mannitol test, and urease and oxidase test were also done to further identify *Enterobacteriaceae* isolates. If not processed immediately, we kept the isolated bacteria at $2-8^{\circ}\text{C}$ in a nutrient broth for not more than 24 hrs until the antimicrobial sensitivity test was done.

2.4. Detection and Confirmation of ESBL Producing *Enterobacteriaceae*. Standard disc diffusion method was used to assess ESBL production among isolated *Enterobacteriaceae* which was then confirmed by the double-disc synergy test (DDST) using third-generation cephalosporins and modified double-disc synergy test using cefepime along with the third-generation cephalosporins, following standard microbiological procedures and the Clinical and Laboratory Standards Institute (CLSI) guidelines [14].

2.5. Procedures for Double-Disc Synergy Test (DDST). Antibiotic discs of 20/10 μg of amoxicillin/clavulanic acid centrally and 30 μg each of cefotaxime and ceftazidime were placed center to center at 15 mm apart, followed by incubation at 37°C for 18-24 hours. ESBL production was considered when inhibition zones of cefotaxime and ceftazidime extending towards clavulanic acid disc. Modified double-disc synergy test using Cefepime antibiotic disc was used to further detect AMPC lactamase coproducing false-negative isolates.

2.6. Procedures for Modified Double-Disc Synergy Test (MDDST). Similar concentrations of amoxicillin-clavulanate antibiotic disc with cephalosporins namely ceftriaxone, cefotaxime, cefepime, and ceftazidime are used in MDDST. Any distortion or increase in the zone of inhibition of the cephalosporin discs towards the amoxicillin-clavulanate disc was considered as confirmatory for ESBLs production.

2.7. Antimicrobial Susceptibility Testing. Kirby-Bauer disk diffusion method was used to assess antimicrobial susceptibility as recommended by the CLSI guidelines [13, 14]. Ampicillin (AMP: 10 μg), ciprofloxacin (CEP: 30 μg), nitrofurantoin (NIF: 300 μg , BD), norfloxacin (NOR: 10 μg), amoxicillin-clavulanic acid (AMC: 20/10 μg), gentamicin (G: 10 μg), trimethoprim-sulfamethoxazole (STX: 1.25/23.75 μg) cefotaxime (CTX: 30 μg), cefoxitin (FOR: 30 μg), ceftriaxone (CTR:

TABLE 1: Demographic and clinical characteristics of study participants among UTI suspected children (<15 years) at HUCSH from February 1 to July 30, 2018, Hawassa, Ethiopia.

Variables	Category	Number	Percentage
Age	0-4 years	159	56.0
	5-9 years	61	21.5
	10-14	64	22.5
Sex	Male	149	52.5
	Female	135	47.5
Place of residence	Urban	174	61.3
	Rural	110	38.7
Patient type	Outpatient	134	47.2
	Inpatient	150	52.8
Malnourished	Yes	57	20.1
	No	227	79.9
Hospital admission within the past 12 months	Yes	96	33.8
	No	188	66.2
Surgery within the past 6 months*	Yes	28	9.9
	No	256	90.1
UTI within the past 12 months	Yes	40	14.1
	No	244	85.9
Paternal education	No education	78	27.5
	Primary	87	30.6
	Secondary and above	119	41.9
Maternal education	No education	109	38.4
	Primary	87	30.6
	Secondary and above	88	31.0
Paternal occupation	Employed	125	44.0
	Merchant	46	16.2
	Farmer	82	28.9
	Daily laborers	31	10.9
Maternal occupation	Housewife	173	60.9
	Employed	61	21.5
	Merchant	50	17.6

30 µg), tetracycline (TE: 30 µg), and meropenem (MEM: 10 µg). Zone of inhibition was measured after overnight incubation at 37°C. Nonsusceptibility to three or more classes of antibiotics defined multidrug resistance.

2.8. Data Analysis. Descriptive data were presented as frequency (percentage), mean (standard deviation), median (range), and using tables and figures. Predictors of infection with ESBL producing *Enterobacteriaceae* were assessed using bivariate logistic regression. Multivariate logistic regression models were run using all variables with a *P* value < 0.25 in univariate analysis. Covariates with a *P* value of <0.05 in the multivariate models were considered as independent predictors of infection with ESBL producing bacteria. Anthropometric *Z*-scores were generated using WHO Anthro plus, while family wealth status was assessed using principal component analysis (PCA).

2.9. Ethical Considerations. The study received ethical approval from the institutional review board (IRB) of Hawassa University (IRB Number: IRB/156/10). Written informed assent was obtained from study participants or caretakers of children. Patient privacy was protected by de-identification of records. Names of patients were coded. All data obtained during the study were kept confidential and were used solely for the purpose of the study. Positive laboratory result from the study participant was communicated to their physicians for appropriate treatment or management.

3. Results

3.1. Demographic and Clinical Characteristics. A total of 284 children ≤14 years of age were included in the study. Of the total study participants, 52.46% (149/284) were male, 61.3% (174/284) were urban residents, 52.8% (150/284) were

TABLE 2: Frequency of ESBL producer and non-ESBL producer *Enterobacteriaceae* isolated from children suspected of UTI at HUCSH from February 1 to July 30, 2018, Hawassa, Ethiopia.

	<i>K. pneumonia</i> No (%)	<i>E. coli</i> No (%)	<i>K. Oxytoca</i> No (%)	<i>K. Ozaenae</i> No (%)	<i>E. cloacae</i> No (%)	<i>P. mirabilis</i> No (%)	<i>C. diversus</i> No (%)	<i>Providencia</i> spp. No (%)	Total
ESBL-producer	14 (70)	12 (37.5)	3 (50)	1 (33.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	30 (41.7)
Non-ESBL producer	6 (30)	20 (62.5)	3 (50)	2 (66.7)	2 (100)	2 (100)	3 (100)	4 (100)	42 (58.3)
Total	20 (100)	32 (100)	6 (100)	3 (100)	2 (100)	2 (100)	3 (100)	4 (100)	72 (100)

treated as inpatient, 20.1% (57/284) had malnutrition, and 9.9% (28/284) underwent surgical procedures in the past 6 months. Subjects with a history of hospital admission and UTI within the past 12 months accounted for 33.8% (96/284) and 14.1% (40/284), respectively (Table 1).


3.2. Frequency of *Enterobacteriaceae* Isolates. From 284 urine specimens, growth was detected in 90 specimens, and a total of 96 (33.8%) bacterial species were identified. Among these, 75% ($n = 72/96$) were *Enterobacteriaceae* with *E. coli* (44.4%, $n = 32/72$), *K. pneumonia* (27.8%, $n = 20/72$), *Klebsiella oxytoca* (8.33%, $n = 6/72$), *Providencia* spp. (5.6%, $n = 4/72$), *Citrobacter diversus* (4.16%, $n = 3/72$), *Enterobacter cloacae* (2.8%, $n = 2/72$), *Proteus mirabilis* (2.8%, $n = 2/72$), and *Klebsiella ozaenae* (4.16%, $n = 3/72$) being most common isolates. The remaining 25% (24/96) from the non-*Enterobacteriaceae* group were *Pseudomonas* spp. (3.12%, $n = 3/96$), *Enterococcus* spp. (11.5%, $n = 11/96$), *S. aureus* (5.21%, $n = 5/96$), *S. saprophyticus* (3.12%, $n = 3/96$), and yeast cell (2.1%, $n = 2/96$) (Table 2).

Enterobacteriaceae were more commonly isolated among female subjects (55.6%, $n = 40/72$) than male subjects (41.7%, $n = 30/72$) (P value = 0.07). Furthermore, *Enterobacteriaceae* were isolated from study subjects who attended inpatient department (59.7%, 43/72), urban (58.3%, 42/72), and aged less than four years (54.2%, 39/72). *Klebsiella* species, 25% (18/72), and *E. coli*, 16.7% (12/72), were the most frequently isolated *Enterobacteriaceae* (Table 2 and Figure 1).

3.3. Prevalence and Predictors of ESBL Producing *Enterobacteriaceae*. Potentially ESBL producing *Enterobacteriaceae* accounted for 58.3% (42/72) of the total isolates, of which 71.4% (30/42) were confirmed as ESBL producers.

We then performed bivariate analysis using paternal occupation, maternal education, paternal education, age, place of residence, patient type, history of UTI within the past 12 months, and family wealth index against ESBL infection. Next, we pooled the variables with a P value < 0.025 to identify independent predictors of infection with ESBL producing *Enterobacteriaceae*. Children with a history of UTI within the past 12 months were less likely to be infected with ESBL producing *Enterobacteriaceae* (AOR = 0.076 with 95% CI (0.010-0.569)). Family wealth index of medium was associated with lower risk of infection by ESBL-producing *Enterobacteriaceae* as compared to those with poor family wealth index (AOR = 0.029 with 95% CI (0.003-0.265)) (Table 3).

3.4. Antibiotic Resistance Profile of Isolated *Enterobacteriaceae*. The antibiotics resistance profile of *Enterobacteriaceae* isolated



RR- relative risk; 95% CI - 95% confidence interval; amox-clav - amoxicillin- clavulanic acid

FIGURE 1: Relative risk of antibiotic resistance in ESBL producers as compared to nonproducers. RR: relative risk; 95% CI: 95% confidence interval; Amox-Clav: amoxicillin-clavulanic acid.

in urine specimen against 12 antibiotics is presented in Tables 4–6. Majority of isolates were resistant to ampicillin (95.8%), amoxicillin/clavulanic acid (94.4%), trimethoprim-sulfamethoxazole (86.1%), and gentamycin (86.1%), while better susceptibility was observed for ciprofloxacin (47.2%), norfloxacin (45.8%), meropenem (40.3%), and nitrofurantoin (26.4%). Of the 72 *Enterobacteriaceae* isolates tested for antibiotic susceptibility testing, 62 (86.1%) were nonsusceptible to three or more drugs belonging to different antibiotics classes. Four (5.6%) of the isolates were nonsusceptible to all antibiotics tested. From ESBL-producing *Enterobacteriaceae*, 96.7% were multidrug resistant.

3.5. Drug Resistance of ESBL-Producing *Enterobacteriaceae*. ESBL-producing *Enterobacteriaceae* were resistant to amoxicillin/clavulanic acid (96.7%), ampicillin (96.7%), trimethoprim-sulfamethoxazole (96.7%), gentamycin (96.7%), cefotaxime (96.7%), ceftriaxone (90%), and tetracycline (86.7%) as compared to ESBL non-producers (Table 6). Except for amoxicillin-clavulanic acid, ampicillin, and ciprofloxacin, the odds of resistance to all other tested antibiotics was significantly higher among ESBL producing *Enterobacteriaceae* as compared to nonproducers (Figure 1).

4. Discussion

Our findings show that urine culture growth was observed in a third of cases presenting with clinically suspected cases of UTI. The majority of bacterial isolates identified in the culture were Gram-negative bacteria, a finding comparable to findings from another tertiary care hospital in Ethiopia [12]. The culture confirmation rate of suspected cases in the current study higher than studies elsewhere [10, 15, 16], reflecting the variability in clinical index of suspicion and

TABLE 3: Bivariate and multivariable analysis of independent variables against ESBL production status among UTI suspected children (<15 years) at HUCSH from February 1, 2018, to July 30, 2018, Hawassa, Ethiopia.

Variable	Category	ESBL producer	ESBL nonproducer	COR (95% CI)	AOR (95% CI)	P value
Age	0-4	11	28	1	1	0.473
	5-9	7	8	0.449 (0.131-1.538)	0.506 (0.078-3.261)	
	10-14	12	6	0.196 (0.059-0.654)	0.183 (0.029-1.157)	
Place of residence	Urban	22	20	1	1	0.142
	Rural	8	22	3.025 (1.101-8.311)	3.900 (0.634-13-984)	
Patient type	Outpatient	16	13	1	1	0.301
	Inpatient	14	29	2.549 (0.966-6.731)	2.546 (0.433-14-958)	
UTI within the past 12 months	No	20	34	1	1	0.012
	Yes	10	8	0.471 (0.160-1.388)	0.076 (0.010-0.569)	
Surgery past 6 months	Yes	6	7	1	NA	
	No	24	35	0.800 (0.239-2.677)		
Paternal occupation	Employee	11	16	1	1	0.086
	Merchant	8	4	0.344 (0.083-1.429)	0.136 (0.14-1.324)	
	Farmer	10	15	1.031 (0.340-3.126)	0.399 (0.027-5.815)	
	Daily laborers	1	7	4.812 (0.517-14-822)	2.669 (0.149-9.061)	
Maternal occupation	Housewife	19	25	1	1	0.362
	Employee	5	6	0.912 (0.242-3.442)	NA	
	Merchant	6	11	1.393 (0.437-4.444)		
Paternal education	No education	8	18	1	1	0.478
	Primary	10	12	0.533 (0.164-1.740)	0.294 (0.021-4.080)	
	Secondary and above	12	12	0.444 (0.140-1.411)	0.309 (0.012-7.908)	
Maternal education	No education	10	20	1	1	0.144
	Primary	12	10	0.417 (0.134-1.292)	0.078 (0.003-2.384)	
	Secondary and above	8	12	0.750 (0.232-2.424)	0.843 (0.020-14.961)	
Family wealth index	Poor	4	10	1	1	0.002
	Medium	23	19	0.330 (0.089-1.224)	0.029 (0.003-0.265)	
	Rich	3	13	1.733 (0.314-9.573)	2.984 (0.144-12.696)	

COR: crude odds ratio; AOR: adjusted odds ratio, *P value < 0.05, NA: not applicable, which is the variable did not meet criterion (P value < 0.25) to be included in multivariate analysis.

the healthcare settings. Important limitations of the current study include that certain clinical features such as ICU admission and circumcision (for boys) were not assessed as potential factors for infection with ESBL producing *Enterobacteriaceae*. Molecular epidemiological characterization of ESBL producing *Enterobacteriaceae* was not possible.

The prevalence of ESBLs producers within the *Enterobacteriaceae* in the study was 41.7%, which is similar to findings in Ethiopia (38.0-51%) [17, 18], Nigeria (47.1%) [19], and India (38.2%) [20]. However, the prevalence of ESBL production in the current study is much lower than that reported from a study at a tertiary facility in Ethiopia [12], which included *Enterobacteriaceae* from specimens other than urine and reported a much smaller number of isolates. The

ESBL prevalence was also lower than those reported in Burkina Faso 58%, from clinical samples [21] and Nepal 62.31% from urinary isolates [22], both of which included adults. On the other hand, the prevalence of ESBL observed in our study was higher than another study in Ethiopia (25%) [23], and studies in Morocco (25.5%) [24], Iran (28.4%) [25], and Korea (16.7%) [26]. The higher prevalence seen in our study compared to developed countries like Greece (10.4%) [27] could be attributed to differences in infection control policies and practices, duration of hospitalization, and improved nursing barriers that decrease acquisition and spread of ESBL producing strains.

Similar to previous reports, *E. coli* was the most common cause of UTI followed by *K. pneumonia* [18, 28, 29]. Even

TABLE 4: Antibacterial resistance levels of *Enterobacteriaceae* isolated from children (<15 years) suspected of UTI in pediatric department at HUCSH from February 1 to July 30, 2018, Hawassa, Ethiopia.

Organism isolated	N	Antibiotics tested											
		AMC	AMP	CIP	GEN	STX	NIF	CTR	FOX	TET	NOR	CXT	MEM
<i>K. pneumoniae</i>	20	19 (95)	19 (95)	7 (35)	17 (85)	17 (85)	7 (35)	17 (85)	11 (55)	17 (85)	8 (40)	15 (75)	11 (55)
<i>E. coli</i>	32	30 (93.8)	29 (90.6)	20 (62.5)	28 (87.5)	29 (90.6)	5 (15.6)	22 (68.8)	22 (68.8)	24 (75)	19 (59.4)	20 (62.5)	6 (18.8)
<i>K. ozaenae</i>	3	3 (100)	3 (100)	0 (0)	3 (100)	2 (66.7)	1 (33.3)	3 (100)	1 (33.3)	3 (100)	0 (0)	2 (66.7)	2 (66.7)
<i>K. oxytoca</i>	6	6 (100)	6 (100)	4 (66.7)	5 (83.3)	6 (100)	4 (66.7)	5 (83.3)	2 (33.3)	4 (66.7)	2 (33.3)	5 (83.3)	4 (66.7)
<i>E. cloacae</i>	2	2 (100)	2 (100)	1 (50)	2 (100)	2 (100)	0 (0)	1 (50)	1 (50)	1 (50)	0 (0)	1 (50)	0 (0)
<i>P. mirabilis</i>	2	2 (100)	2 (50)	0 (0)	2 (100)	2 (100)	0 (0)	0 (0)	2 (100)	1 (50)	1 (50)	0 (0)	0 (0)
<i>C. diversus</i>	3	3 (100)	3 (100)	1 (33.3)	2 (66.7)	2 (66.7)	0 (0)	2 (66.7)	2 (66.7)	2 (66.7)	2 (66.7)	2 (66.7)	2 (66.7)
<i>Providencia spp.</i>	4	4 (100)	4 (100)	1 (25)	3 (75)	2 (50)	2 (50)	4 (100)	2 (50)	2 (50)	1 (25)	3 (75)	4 (100)
Total	72	69 (95.8)	68 (94.4)	34 (47.2)	62 (86.1)	62 (86.1)	19 (26.4)	54 (75)	43 (59.7)	54 (75)	33 (45.8)	49 (68)	29 (40.3)

Abbreviations: AMC: amoxicillin/clavulanate; AMP: ampicillin; CIP: ciprofloxacin; GN: gentamicin; STX: trimethoprim-sulfamethoxazole; NIF: nitrofurantoin; CTR: ceftriaxone; FOX: ceftoxitin; TET: tetracycline; NOR: norfloxacin; CXT: cefotaxime; MEM: meropenem.

TABLE 5: Multidrug resistance level of *Enterobacteriaceae* isolated from children (<15 years) suspected of UTI in pediatric department at HUCSH from February 1 to July 30, 2018, Hawassa, Ethiopia.

Isolates (number)	Level of antibiotics resistance (number (%))								Total MDR-E (>R3)
	R0	R1	R2	R3	R4	R5	R6	R7	
<i>E. coli</i> (32)	0 (0.0)	1 (3.1)	2 (6.3)	8 (25)	7 (21.9)	7 (21.9)	4 (12.5)	3 (9.4)	29 (90.6)
<i>K. pneumonea</i> (20)	0 (0.0)	1 (5.0)	2 (10.0)	8 (40.0)	4 (20.0)	3 (15.0)	1 (5.0)	1 (5.0)	17 (85.0)
<i>K. ozaenae</i> (3)	0 (0.0)	0 (0.0)	0 (0.0)	2 (66.7)	0 (0.0)	0 (0.0)	1 (33.3)	0 (0.0)	3 (100)
<i>K. oxytoca</i> (6)	0 (0.0)	1 (16.7)	1 (16.7)	1 (16.7)	0 (0.0)	2 (33.3)	0 (0.0)	1 (16.7)	4 (66.7)
<i>E. cloacae</i> (2)	0 (0.0)	0 (0.0)	0 (0.0)	1 (50.0)	1 (50.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (100)
<i>Citrobacter diversus</i> (3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (33.3)	0 (0.0)	1 (33.3)	0 (0.0)	2 (66.7)
<i>P. mirabilis</i> (2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (50.0)	1 (50.0)	0 (0.0)	0 (0.0)	2 (100)
<i>Providencia spp.</i> (4)	0 (0.0)	1 (25.0)	0 (0.0)	1 (25.0)	0 (0.0)	2 (50.0)	0 (0.0)	0 (0.0)	3 (75.0)
Total (72)									62 (86.1)

though *E. coli* had high isolation rate (44.4%) in the study, *Klebsiella* spp. was identified as the major ESBL producer 25% (18/72) followed by *E. coli* 16.7% (12/72). A similar trend was reported by studies in Ethiopia and Pakistan [17, 30], while more ESBL production in *E. coli* as compared to *K. pneumoniae* in another study in Ethiopia [12].

A worrying level of multidrug resistance was reported in our study which adds to previous reports in other facilities in Ethiopia, for example, 87.4% in Northwest Ethiopia [1] and 68.3% in Addis Ababa, Ethiopia [18]. Studies elsewhere also reported similarly high isolation rates of multidrug-resistant bacteria, for instance in Chicago, USA, 76% [31], Nepal 64.04% [32], and Iran 52.7% [29]. Unsurprisingly, ESBL-producing *Enterobacteriaceae* are associated with multidrug resistance in nearly all the cases (96.7%)—a finding very close to another survey in Addis Ababa, Ethiopia, with 96.3% multidrug resistance [18]. Nitrofurantoin demonstrated a lower

level of resistance among *E. coli* and *K. pneumoniae* isolates, favoring the use of this antibiotic for empiric treatment of UTI in children. The lower resistance levels could point to the lower utilization of the antibiotic [33]. Our finding together with similar previous studies underscore the contribution of ESBL producing *Enterobacteriaceae* spp in multidrug resistance outbreaks in healthcare facilities. The findings call for an urgent assessment of the national burden of ESBL-producing *Enterobacteriaceae* which cause UTI and other clinical diseases including the antimicrobial susceptibility patterns. Such efforts would have paramount importance to guide local treatment and care guidelines.

Antibiotic resistance levels of *Enterobacteriaceae* are reported to be high in several resource-limited settings. For example, in Iran, resistance to trimethoprim-sulfamethoxazole (93.6%), ciprofloxacin (40.4%), and tetracycline (84.5%) [29] was reported. Similarly, in Bangladesh, 97.8% for trimethoprim-sulfamethoxazole

TABLE 6: Antibacterial resistance levels of ESBL-producing and non-ESBL-producing *Enterobacteriaceae* among UTI-suspected children (<15 years) at HUCSH from February 1 to July 30, 2018, Hawassa, Ethiopia.

Drugs	ESBL producer (30) n (% of NS*)	ESBL nonproducer (42) n (% of NS)	P value
Amoxicillin-clavulanic acid	29 (96.7)	40 (95.2)	0.63
Ampicillin	29 (96.7)	39 (92.9)	0.44
Ciprofloxacin	17 (56.7)	17 (40.5)	0.13
Gentamycin	29 (96.7)	33 (78.6)	0.028
Co-trimoxazole	29 (96.7)	33 (78.6)	0.028
Nitrofurantoin	12 (40)	7 (16.7)	0.026
Ceftriaxone	27 (90)	27 (64.3)	0.012
Cefoxitin	23 (76.7)	20 (47.6)	0.012
Tetracycline	26 (86.7)	28 (66.7)	0.047
Norfloxacin	20 (66.7)	13 (30.9)	0.003
Cefotaxime	29 (96.7)	20 (47.6)	<.0001
Meropenem	17 (56.7)	12 (28.6)	0.012

NS*: nonsusceptible.

was reported [34]. These figures are considerably lower in high-income countries, for example, in the United States, resistance to ampicillin (55%), amoxicillin/clavulanic acid (10%), trimethoprim-sulfamethoxazole (24%), and nitrofurantoin (14%) of *Enterobacteriaceae* was reported [31]. These findings present a concerning public health problem, which requires a coordinated action to generate more data in understanding the magnitude of the problem and designing interventions that help to mitigate the issue.

5. Conclusion

Our research finding evidenced that ESBL-producing bacteria are prevalent among children with UTI. From the total bacteria species isolated, *Enterobacteriaceae* contributed to the majority of the isolates. Most of the *Enterobacteriaceae* were isolated from patients who attended inpatient department. ESBL-producing *Klebsiella* species were the most frequent *Enterobacteriaceae* followed by *E. coli*. Majority of *Enterobacteriaceae* had resistance to commonly prescribed antibiotics. The drug with preserved efficacy for ESBL producers and non-ESBL producers is nitrofurantoin.

Data Availability

Data can be provided by the principal investigator upon reasonable request.

Conflicts of Interest

The authors declare that they have no competing interests.

Authors' Contributions

AA conceived the study, analyzed and interpreted the data, and prepared the manuscript draft. BTT guided the analysis, interpreted the data, and helped in drafting the manuscript. MW and DN conceived the study and helped during analysis, and BL helped during analysis.

Acknowledgments

We would like to thank Hawassa University College of Medicine and Health Sciences for technical support. An earlier version of this work has been presented as a preprint: <https://www.researchsquare.com/article/rs-11485/v1>.

References

- [1] S. Eshetie, C. Unakal, A. Gelaw, B. Ayelign, M. Endris, and F. Moges, "Multidrug resistant and carbapenemase producing *Enterobacteriaceae* among patients with urinary tract infection at referral Hospital, Northwest Ethiopia," *Antimicrobial Resistance and Infection Control*, vol. 4, no. 1, 2015.
- [2] T. Gezmu, B. Regassa, A. Manilal, and M. Mama, "Prevalence, diversity and antimicrobial resistance of bacteria isolated from the UTI patients of Arba Minch Province, southern Ethiopia," *Translational Biomedicine*, vol. 7, no. 3, 2016.
- [3] Y. H. Kim, E. M. Yang, and C. J. Kim, "Urinary tract infection caused by community-acquired extended-spectrum β -lactamase-producing bacteria in infants," *Jornal de Pediatria*, vol. 93, no. 3, pp. 260–266, 2017.
- [4] A. Chander and C. D. Shrestha, "Prevalence of extended spectrum beta lactamase producing *Escherichia coli* and *Klebsiella pneumoniae* urinary isolates in a tertiary care hospital in Kathmandu, Nepal," *BMC Research Notes*, vol. 6, no. 1, 2013.
- [5] E. Mahesh, D. Ramesh, V. A. Indumathi, M. W. Khan, P. S. Kumar, and K. Punith, "Risk factors for community acquired urinary tract infection caused by ESBI-producing bacteria," *Journal, Indian Academy of Clinical Medicine*, vol. 11, no. 4, pp. 271–276, 2010.
- [6] S. Chandra, "Extended-spectrum beta-lactamase infections," *Curr Emerg Hosp Med Rep.*, vol. 1, no. 3, pp. 145–148, 2013.
- [7] CDC, *Antibiotic resistance threats in the United States In. U.S. department of health and human services: centers for disease control and prevention*, Antibiotic resistance threats in the United States, USA, 2013.
- [8] M. E. Rupp and P. D. Fey, "Extended Spectrum??-Lactamase (ESBL)-producing *Enterobacteriaceae*," *Drugs*, vol. 63, no. 4, pp. 353–365, 2003.
- [9] B. T. Tadesse, E. A. Ashley, S. Ongarello et al., "Antimicrobial resistance in Africa: a systematic review," *BMC Infectious Diseases*, vol. 17, no. 1, p. 616, 2017.
- [10] C. M. Muvunyi, F. Masaisa, A. Musemakweri et al., "Decreased susceptibility to commonly used antimicrobial agents in bacterial pathogens isolated from urinary tract infections in Rwanda: need for new antimicrobial guidelines," *The American Journal of Tropical Medicine and Hygiene*, vol. 84, no. 6, pp. 923–928, 2011.
- [11] K. Desta, Y. Woldeamanuel, A. Azazh et al., "High gastrointestinal colonization rate with extended-spectrum β -lactamase-producing *Enterobacteriaceae* in hospitalized patients:

- emergence of carbapenemase-producing *K. pneumoniae* in Ethiopia,” *PLOS ONE*, vol. 11, no. 8, article e0161685, 2016.
- [12] M. H. Legese, G. Mulugeta, and A. D. Weldearegay, “Extended-spectrum beta-lactamase- and carbapenemase-producing *Enterobacteriaceae* among Ethiopian children,” *Infection and Drug Resistance*, vol. Volume 10, pp. 27–34, 2017.
- [13] M. Cheesbrough, *District Laboratory Practice in Tropical Countries*, Published in the United States of America by Cambridge University Press, New York, 2006.
- [14] CLSI, *Performance Standards for Antimicrobial Susceptibility Testing. In: 27th Edition, CLSI Supplement M100*, Wayne, PA, Clinical and Laboratory standards institute, 2017.
- [15] B. Abera, M. Kibret, and W. Mulu, “Extended-spectrum beta (β)-lactamases and Antibiogram in *Enterobacteriaceae* from clinical and drinking water Sources from Bahir Dar City, Ethiopia,” *PLOS ONE*, vol. 11, no. 11, article e0166519, 2016.
- [16] C. M. Ogbukagu, V. N. Anakwenze, C. C. Ekwealor, C. C. Ezemba, and I. A. Ekwealor, “Incidence of urinary tract infections (UTI) amongst patients attending primary health centres in Anambra state,” *Advances in Microbiology*, vol. 6, no. 7, pp. 537–547, 2016.
- [17] S. M. Siraj, S. Ali, and B. Wondafrash, “Extended-spectrum β -lactamase production in *Klebsiella pneumoniae* and *Escherichia coli* at Jimma University specialized hospital, south-west,” *Ethiopia. Molecular Microbiology Research*, vol. 5, no. 1, pp. 1–9, 2015.
- [18] D. S. Teklu, A. A. Negeri, M. H. Legese, T. L. Bedada, H. K. Woldemariam, and K. D. Tullu, “Extended-spectrum beta-lactamase production and multi-drug resistance among *Enterobacteriaceae* isolated in Addis Ababa, Ethiopia,” *Antimicrobial Resistance and Infection Control*, vol. 8, no. 1, 2019.
- [19] I. Azekhueme, A. E. Moses, and S. D. Abbey, “Extended spectrum beta-lactamases in clinical isolates of *Escherichia coli* and *Klebsiella pneumoniae* from University of Uyo Teaching Hospital, Uyo-Nigeria,” *Journal of Advances in Medical and Pharmaceutical Sciences*, vol. 2, no. 3, pp. 117–125, 2015.
- [20] L. Segar, S. Kumar, N. M. Joseph, and U. Sivaraman, “Prevalence of extended spectrum beta-lactamases among *Enterobacteriaceae* and their anti-biogram pattern from various clinical samples,” vol. 8, no. 5, pp. 220–223, 2015, <https://innovareacademics.in/journals/index.php/ajpcr/article/view/7416>.
- [21] A.-S. Ouedraogo, M. Sanou, A. Kissou et al., “High prevalence of extended-spectrum β -lactamase producing *enterobacteriaceae* among clinical isolates in Burkina Faso,” *BMC Infectious Diseases*, vol. 16, no. 1, 2016.
- [22] K. Yadav and S. Prakash, “Screening of ESBL producing multidrug resistant *E. coli* from Urinary tract infection suspected cases in southern Terai of Nepal,” *Journal of Infectious Diseases and Diagnosis*, vol. 2, no. 2, 2017.
- [23] L. G. Selassie, “Prevalence of extended spectrum beta-lactamase producing *Enterobacteriaceae*: a cross sectional study at Adama Hospital, Adama, Ethiopia,” *Journal of Emerging Infectious Diseases*, vol. 1, no. 1, 2016.
- [24] M. C. El Bouamri, L. Arsalane, Y. El Kamouni, and S. Zouhair, “Antimicrobial susceptibility of urinary *Klebsiella pneumoniae* and the emergence of carbapenem-resistant strains: a retrospective study from a university hospital in Morocco, North Africa,” *African Journal of Urology*, vol. 21, no. 1, pp. 36–40, 2015.
- [25] A. Khaleedi, D. Esmaeili, K. Esmaeili et al., “Prevalence of extended-spectrum- β -lactamase-producing *Escherichia coli* isolates among uropathogens in a pediatrics hospital,” *Der Pharma Chemica*, vol. 8, no. 3, pp. 161–165, 2016.
- [26] Y. H. Kima, E. M. Yanga, and C. J. Kima, “Urinary tract infection caused by community-acquired extended-spectrum-lactamase-producing bacteria in infants journal of pediatric,” vol. 93, no. 3, pp. 260–266, 2017.
- [27] J. Dotis, N. Printza, A. Marneri, D. Gidaris, and F. Papachristou, “Urinary tract infections caused by extended-spectrum beta-lactamase-producing bacteria in children: a matched case-control study,” *The Turkish Journal of Pediatrics*, vol. 55, no. 6, pp. 571–574, 2013.
- [28] G. Beyene and W. Tsegaye, “Bacterial uropathogens in urinary tract infection and antibiotic susceptibility pattern in Jimma University Specialized Hospital, Southwest Ethiopia,” *Ethiopian Journal of Health Science*, vol. 21, no. 2, 2011.
- [29] S. A. Shahla Mansouri, “Prevalence of multiple drug resistant clinical isolates of extended-spectrum beta-lactamase producing *Enterobacteriaceae* in Southeast Iran,” *Iran journal of Medical Sciences*, vol. 35, no. 2, pp. 101–108, 2010.
- [30] F. I. Afridi, B. J. Farooqi, and A. Hussain, “Frequency of extended spectrum beta lactamase producing *enterobacteriaceae* among urinary pathogen isolates,” *Journal of the College of Physicians and Surgeons Pakistan*, vol. 21, no. 12, pp. 741–744, 2011.
- [31] T. Khawcharoenporn, S. Vasoo, and K. Singh, “Urinary tract infections due to Multidrug-Resistant *Enterobacteriaceae*: prevalence and risk factors in a Chicago Emergency Department,” *Emergency Medicine International*, vol. 2013, 7 pages, 2013.
- [32] S. Thakur, N. Pokhrel, and M. Sharma, “Prevalence of multi-drug resistant *Enterobacteriaceae* and extended spectrum β lactamase producing *Escherichia coli* in urinary tract infection,” *Research Journal of Pharmaceutical, Biological and Chemical Sciences*, vol. 4, no. 2, 2013.
- [33] B. J. Gardiner, A. J. Stewardson, I. J. Abbott, and A. Y. Peleg, “Nitrofurantoin and fosfomycin for resistant urinary tract infections: old drugs for emerging problems,” *Australian Prescriber*, vol. 42, no. 1, pp. 14–19, 2019.
- [34] N. Akhtar, R. Rahman, and S. Sultana, “Antimicrobial sensitivity pattern of *Escherichia coli* causing urinary tract infection in Bangladeshi patients,” *American Journal of Microbiological Research*, vol. 4, no. 4, 2016.